Dina M. Kweekel

848 total citations
19 papers, 628 citations indexed

About

Dina M. Kweekel is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Dina M. Kweekel has authored 19 papers receiving a total of 628 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Pharmacology. Recurrent topics in Dina M. Kweekel's work include Cancer therapeutics and mechanisms (5 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers) and Innovative Microfluidic and Catalytic Techniques Innovation (2 papers). Dina M. Kweekel is often cited by papers focused on Cancer therapeutics and mechanisms (5 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers) and Innovative Microfluidic and Catalytic Techniques Innovation (2 papers). Dina M. Kweekel collaborates with scholars based in Netherlands, United States and Australia. Dina M. Kweekel's co-authors include Henk‐Jan Guchelaar, Hans Gelderblom, Tahar van der Straaten, Ninja Antonini, Cornelis J.A. Punt, Jesse J. Swen, Dirk Jan A. R. Moes, Johan W. de Fijter, J.W.R. Nortier and Paul J. M. van der Boog and has published in prestigious journals such as British Journal of Cancer, International Journal of Pharmaceutics and European Journal of Cancer.

In The Last Decade

Dina M. Kweekel

17 papers receiving 618 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dina M. Kweekel Netherlands 12 300 259 89 69 62 19 628
Alice Chin United States 14 223 0.7× 426 1.6× 109 1.2× 24 0.3× 57 0.9× 24 1.1k
Alan Le Canada 10 347 1.2× 173 0.7× 52 0.6× 48 0.7× 27 0.4× 13 939
A. Zeevi United States 18 103 0.3× 135 0.5× 55 0.6× 17 0.2× 49 0.8× 36 748
Marius Dohse Germany 9 497 1.7× 230 0.9× 49 0.6× 25 0.4× 157 2.5× 13 788
Hiroyoshi Maeda Japan 13 383 1.3× 273 1.1× 178 2.0× 39 0.6× 32 0.5× 29 695
Hillard Lazarus United States 11 163 0.5× 220 0.8× 44 0.5× 59 0.9× 59 1.0× 17 699
Hiroyuki Hamada Japan 10 563 1.9× 447 1.7× 43 0.5× 21 0.3× 73 1.2× 37 980
Liping Dou China 17 113 0.4× 484 1.9× 75 0.8× 53 0.8× 12 0.2× 101 962
Naruhiko Mizuta Japan 15 106 0.4× 252 1.0× 143 1.6× 94 1.4× 12 0.2× 44 683
Rui Caetano Oliveira Portugal 15 223 0.7× 172 0.7× 100 1.1× 63 0.9× 11 0.2× 98 719

Countries citing papers authored by Dina M. Kweekel

Since Specialization
Citations

This map shows the geographic impact of Dina M. Kweekel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dina M. Kweekel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dina M. Kweekel more than expected).

Fields of papers citing papers by Dina M. Kweekel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dina M. Kweekel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dina M. Kweekel. The network helps show where Dina M. Kweekel may publish in the future.

Co-authorship network of co-authors of Dina M. Kweekel

This figure shows the co-authorship network connecting the top 25 collaborators of Dina M. Kweekel. A scholar is included among the top collaborators of Dina M. Kweekel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dina M. Kweekel. Dina M. Kweekel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Desar, Ingrid M.E., et al.. (2023). Results of the first international quality control programme for oral targeted oncolytics. British Journal of Clinical Pharmacology. 90(1). 336–343.
3.
Kweekel, Dina M., Brenda C. M. de Winter, Jesse J. Swen, et al.. (2023). Development and Bioequivalence of 3D‐Printed Medication at the Point‐of‐Care: Bridging the Gap Toward Personalized Medicine. Clinical Pharmacology & Therapeutics. 113(5). 1125–1131. 23 indexed citations
4.
Kweekel, Dina M., et al.. (2023). Busulfan Interlaboratory Proficiency Testing Program Revealed Worldwide Errors in Drug Quantitation and Dose Recommendations. Therapeutic Drug Monitoring. 45(6). 760–765. 6 indexed citations
5.
Kweekel, Dina M., et al.. (2021). 3D printed furosemide and sildenafil tablets: Innovative production and quality control. International Journal of Pharmaceutics. 603. 120694–120694. 27 indexed citations
6.
McCune, Jeannine S., Arjen M. Punt, Rosa F. Yeh, et al.. (2021). Quality Control of Busulfan Plasma Quantitation, Modeling, and Dosing: An Interlaboratory Proficiency Testing Program. Therapeutic Drug Monitoring. 43(5). 657–663. 7 indexed citations
7.
Dijkmans, Anneke C., Dina M. Kweekel, Craig Balmforth, et al.. (2019). The simplified oral flucloxacillin absorption test: an accurate method to identify patients with inadequate oral flucloxacillin absorption.. PubMed. 77(7). 255–260. 5 indexed citations
8.
Zwart, Tom C., Paul J. M. van der Boog, Johan W. de Fijter, et al.. (2018). Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device. British Journal of Clinical Pharmacology. 84(12). 2889–2902. 78 indexed citations
9.
Lankheet, Nienke A. G., Ingrid M.E. Desar, Sasja F. Mulder, et al.. (2017). Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. British Journal of Clinical Pharmacology. 83(10). 2195–2204. 62 indexed citations
10.
Dias, Mafalda M., Jean‐Pierre Pignon, Christos S. Karapetis, et al.. (2014). The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. The Pharmacogenomics Journal. 14(5). 424–431. 32 indexed citations
11.
Kweekel, Dina M., Xiaobo Lu, Kees L. M. C. Franken, et al.. (2013). Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 759. 37–44. 12 indexed citations
12.
Kweekel, Dina M., Hans Gelderblom, Miriam Koopman, et al.. (2013). Concordance of Genotype for Polymorphisms in DNA Isolated from Peripheral Blood and Colorectal Cancer Tumor Samples. Pharmacogenomics. 14(16). 2005–2012. 22 indexed citations
13.
Kweekel, Dina M., Miriam Koopman, Ninja Antonini, et al.. (2008). GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. British Journal of Cancer. 99(8). 1316–1321. 26 indexed citations
14.
Kweekel, Dina M., Hans Gelderblom, Tahar van der Straaten, et al.. (2008). UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. British Journal of Cancer. 99(2). 275–282. 59 indexed citations
15.
Kweekel, Dina M., Hans Gelderblom, Ninja Antonini, et al.. (2008). Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. European Journal of Cancer. 45(4). 572–578. 44 indexed citations
16.
Kweekel, Dina M., Henk‐Jan Guchelaar, & Hans Gelderblom. (2008). Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treatment Reviews. 34(7). 656–669. 76 indexed citations
17.
Straaten, Tahar van der, et al.. (2006). Multiplex Pyrosequencing of Two Polymorphisms in DNA Repair Gene XRCC1. Journal of Molecular Diagnostics. 8(4). 444–448. 9 indexed citations
18.
Kweekel, Dina M., Hans Gelderblom, & Henk‐Jan Guchelaar. (2005). Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treatment Reviews. 31(2). 90–105. 138 indexed citations
19.
Kweekel, Dina M., et al.. (2004). Outcomes of an antimicrobial control program in a Dutch hospital. American Journal of Health-System Pharmacy. 61(16). 1702–1706. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alice Chin Breakdown of academic impact, for papers by Alan Le Breakdown of academic impact, for papers by A. Zeevi Breakdown of academic impact, for papers by Marius Dohse Breakdown of academic impact, for papers by Hiroyoshi Maeda Breakdown of academic impact, for papers by Hillard Lazarus Breakdown of academic impact, for papers by Hiroyuki Hamada Breakdown of academic impact, for papers by Liping Dou Breakdown of academic impact, for papers by Naruhiko Mizuta Breakdown of academic impact, for papers by Rui Caetano Oliveira
Rankless by CCL
2026